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DNA methylation is an epigenetic alteration, involved in
human cancers. “Field cancerization”,a l s ok n o w na s
“field defect” in cancerogenesis has been explained by
the presence of cells with genetic and epigenetic altera-
tions, which are predisposed to cancer development.
DNA methylation has been proposed as a candidate
mediator of this field cancerization.
The aim of the study was to assess the methylation
status of 6 genes promoter (MGMT, APC, TIMP3,
RAR, ECAD and p16) in the tumor and in the adjacent
normal tissue in patients suffering from head and neck
squamous cell carcinoma (HNSCC).
The samples of tumor and adjacent normal tissue were
obtained during surgery from 55 patients hospitalized at
Maria Skłodowska-Curie Cancer Center and Institute of
Oncology, Gliwice. After DNA isolation the methylation-
specific polymerase chain reaction (MSP) was used to
analyze the methylation status of the gene promoter
mentioned above. Conventional histopathological para-
meters were assessed to prove the presence of squamous
cell carcinoma while no neoplastic changes were detected
histopathologically in the adjacent normal tissue. In order
to establish the clinical relevance of methylation in
HNSCC, correlation between methylation frequency of
these genes promoter as well as the clinical stage of
tumor, the patient’s age and gender were also considered.
Ethics approval for this study was received from the
Maria Skłodowska-Curie Cancer Center and Institute of
Oncology Ethics Committee (No. KB/493-31/08).
Methylation of MGMT, APC, TIMP3, RAR, ECAD
and p16 were detected in 38%, 33%, 61%, 67%, 29%,
49% of tumors, respectively. Some of the patients who
delivered methylation–positive tumor samples, had also
methylation–positive adjacent normal tissues. The genes
promoter methylation were present in 20%, 31%, 39%,
49%, 11%, 42% of the tumor-adjacent normal tissues,
respectively.
To sum up, the epigenetic modifications represented
by DNA methylation in the adjacent normal tissue in
t h ec o u r s eo fH N S C Cp o i n tt ot h eu s e f u l n e s so fD N A
methylation as a marker of epigenetic cancerization field
and of the future risk of cancer development.
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